



12/16/04

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Georges et al. Art Unit: 1645
Serial No.: 10/736,889 Examiner: TBA
Date Filed: December 15, 2003 Conf. No. TBA
Docket Nos.: AUR-013US and 112418.147 Cust. No.: 23483
Title: VIMENTIN DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (Label No. EV610872065US) under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12/15/04
Date

AMANDA RIPLEY
Printed Name

Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants submit herewith the references on the attached Form PTO-1449. Copies of the cited U.S. patent references, U.S. published application references and pending U.S. application references are not enclosed as the Applicants believe that they are available to the Examiner via the PTO's internal database. Copies of the aforementioned references can be provided to the Examiner upon his/her request. Copies of all other cited references are enclosed herewith.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (b) (3), before the mailing of a first Office Action on the merits, therefore no fee is due.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be material to patentability. Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents constitute prior art under United States law, Applicants reserve the right to

Information Disclosure Statement

Appln. No. 10/736,889

Page 2

present to the Office relevant facts and law regarding the significance of such documents to the patentability of the claimed invention.

It is respectfully requested that the Examiner initial and return a copy of the attached Form PTO-1449 with the next Patent Office communication.

No fees are believed to be due in connection with this submission; however, please charge any fees that might be due to Deposit Account Number 08-0219. If there are any questions, the Examiner is invited to call the undersigned at the telephone number indicated below.

Respectfully submitted,

Date: 12/15/04

Ann-Louise Kerner
Ann-Louise Kerner, Ph.D.
Reg. No. 33,523

WILMER CUTLER PICKERING HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

7

Application Number	10/736,889
Filing Date	12/15/2003
First Named Inventor	Georges et al.
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	112418.147/AUR-013

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 4,720,386	01/19/1988	McCollester	
		US- 5,194,384	03/16/1993	Bystryn	
		US- 5,407,653	04/18/1995	Piwnica-Worms	
		US- 6,338,853 B1	01/15/2002	Bystryn	
		US- 6,352,996 B1	03/05/2002	Cao et al.	
		US- 6,406,689 B1	06/18/2002	Falkenberg et al.	
		US- 6,417,336	07/09/2002	Morishima et al.	
		US- 6,476,193	11/05/2002	Nandabalan et al.	
		US- 6,511,676 B1	01/28/2003	Boulikas	
		US- 6,562,347 B1	05/13/2003	Kwak et al.	
		US- 6,572,856 B1	06/03/2003	Taylor et al.	
		US- 6,593,087 B2	07/15/2003	Prichard et al.	
		US- 6,623,923 B1	09/23/2003	Xu et al.	
		US- 6,630,327 B1	10/07/2003	Mechetner et al.	
		US- 6,657,048 B2	12/02/2003	Young et al.	
		US- 20020061316A1	05/23/2002	Srivastava	
		US- 20020198139A1	12/26/2002	Deutschman et al.	
		US- 20030012793A1	01/16/2003	Srivastava et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
.....
.....
.....
.....

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

7

Application Number	10/736,889
Filing Date	12/15/2003
First Named Inventor	Georges et al.
Art Unit	1645
Examiner Name	TBA
Attorney/Docket Number	112418-147/AUR-013

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 20030012794A1	01/16/2003	Srivastava et al.	
		US- 20030031661A1	02/13/2003	Graner et al.	
		US- 20030087412A1	05/08/2003	Nandabalan et al.	
		US- 20030157081A1	08/21/2003	Bonini et al.	
		US- 20030165519A1	09/04/2003	Srivastava	
		US- 20030180721A1	09/25/2003	Witkin	
		US- 10/801,988	03/15/2004	Georges et al.	
		US- 10/736,889	12/15/2003	Georges et al.	
		US- 20040185511A1	09/23/2004	Georges et al.	
		US- 5,801,154	09/01/1998	Frank et al.	
		US- 2002110912A1	08/15/2002	Jatinder et al.	
US-					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 02/071061A	09/12/2002	Gabor et al.		
		WO 03/008542A	01/30/2003	Scherf et al.		
		EP 0813872A	12/29/1997	Kureha Chemical		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

7

Complete if Known

<i>Application Number</i>	10/736,889
<i>Filing Date</i>	12/15/2003
<i>First Named Inventor</i>	Georges et al.
<i>Art Unit</i>	1645
<i>Examiner Name</i>	TBA
<i>Attorney Docket Number</i>	112418.147/AUR-013

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ABOU-JAWDE et al., An Overview of Targeted Treatments in Cancer, Clinical Therapeutics, Vol. 25, No. 8, 2003, pp. 2121-2137	/
		ALQAWI and GEORGES, The multidrug resistance protein ABCC1 drug-binding domains show selective sensitivity to mild detergents, Biochemical and Biophysical Research Communications 303, 2003, pp. 1135-1141	/
		BARRETO et al., Stress-induced release of HSC70 from human tumors, Cellular Immunology 222, 2003, pp. 97-104	/
		CHENG et al., Retaining of the Assembly Capability of Vimentin Phosphorylated by Mitogen-Activated Protein Kinase-Activated Protein Kinase-2, Journal of Cellular Biochemistry, 89, 2003, pp. 589-602	/
		DEN BOER et al., Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia, Blood, Vol. 91, No. 6, 1998, pp. 2092-2098	/
		DI PIETRO et al., Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters, Cell. Mol. Life Sci. 59, 2002, pp. 307-322	/
		DU et al., Dual Requirement for Rho and Protein Kinase C in Direct Activation of Phospholipase D1 Through G Protein-coupled Receptor Signaling, Molecular Biology of the Cell, Vol. 11, 2000, pp. 4359-4368	/
		DURBIN et al., An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3, Proc. Natl. Acad. Sci. USA, Vol. 91, 1994, pp. 4313-4317	/
		FAIGLE et al., Vimentin Filaments in Fibroblasts Are a Reservoir for SNAP23, a Component of the Membrane Fusion Machinery, Molecular Biology of the Cell, Vol. 11, 2000, pp. 3485-3494	/
		FEIG, Designer Drugs: New Directed Therapies for Cancer, International Journal of Hematology Suppl. II, 76, 2002, pp. 281-283	/

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

7

Complete if Known	
Application Number	10/736,889
Filing Date	12/15/2003
First Named Inventor	Georges et al.
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	112418.147/AUR-013

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FUJITA et al., High Molecular Weight Vimentin Complex Is Formed after Proteolytic Digestion of Vimentin by Caspase-3: Detection by Sera of Patients with Interstitial Pneumonia, <i>Microbiol Immunol.</i> , 47(6), 2003, pp. 447-451	✓
		GARNETT, Targeted drug conjugates: principles and progress, <i>Advanced Drug Delivery Reviews</i> , 53, 2001, pp. 171-216	✓
		GOTO et al., Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK), <i>Genes to Cells</i> , 7, 2002, pp. 91-97	✓
		GRATAMA et al., Flow Cytometric Quantitation of Immunofluorescence Intensity: Problems and Perspectives, <i>Cytometry</i> 33, 1998, pp. 166-178	✓
		HEIDENTHAL et al., The Binding in Vitro of Modified LDL to the Intermediate Filament Protein Vimentin, <i>Biochemical and Biophysical Research Communications</i> , 267, 2000, pp. 49-53	✓
		HERRMANN and AEBI, Intermediate filaments and their associates: multi-talented structural elements specifying cytoarchitecture and cytodynamics, <i>Current Opinion in Cell Biology</i> , 12, 2000, pp. 79-90	✓
		HUBERT et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, <i>PNAS</i> , Vol. 96, No. 25, 1999, pp. 14523-14528	✓
		IQBAL and LENZ, Targeted Therapy and Pharmacogenomic Programs, <i>Cancer Supplement</i> , Vol. 97, No. 8, 2003, pp. 2076-2082	✓
		KIM et al., Multidrug Resistance-Associated Protein (MRP) is expressed in osteosarcoma but is not a significant mechanism of drug resistance, 47th Ann. Mtg., Orthopaedic Research Society, 2001, p. 0855	✓
		KIM, Targeted therapies for the treatment of cancer, <i>The American Journal of Surgery</i> , 186, 2003, pp. 264-268	✓

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

7

Complete If Known

Application Number	10/736,889
Filing Date	12/15/2003
First Named Inventor	Georges et al.
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	112418.147/AUR-013

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KOWN et al., In Vivo Imaging of Acute Cardiac Rejection in Human Patients Using 99m Technetium Labeled Annexin V, American Journal of Transplantation, 1, 2001, pp. 270-277	/
		KREITMAN and PASTAN, Immunotoxins for targeted cancer therapy, Advanced Drug Delivery Reviews, 31, 1998, pp. 53-88	/
		LING, Multidrug resistance: molecular mechanisms and clinical relevance, Cancer Chemother. Pharmacol., 40 Suppl., 1997, pp. S3-S8	/
		MESCHINI et al., Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells, Int. J. Cancer, 87, 2000, pp. 615-628	/
		MOR-VAKNIN et al., Vimentin is secreted by activated macrophages, Nature Cell Biology, Vol, 5, 2003, pp. 59-63	/
		PARK, Tumor-directed Targeting of Liposomes, Bioscience Reports., Vol. 22, No. 2, 2002, pp. 267-281	/
		PATTERSON et al., Reduced Numatrin/B23/Nucleophosmin Labeling in Apoptotic Jurkat T-lymphoblasts, The Journal of Biological Chemistry, Vol, 270, No. 16, 1995, pp. 9429-9436	/
		ROTS et al., Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors, Journal of Controlled Release, 87, 2003, pp. 159-165	/
		ROWLINSON-BUSZA and EPENETOS, Targeted delivery of biologic and other antineoplastic agents, Current Opinion in Oncology, 4, 1992, 1142-1148	/
		SCHROEIJERS et al., the Mr 193,000 Vault Protein Is Up-Regulated in Multidrug-resistant Cancer Cell Lines, Cancer Research, 60, 2000, pp. 1104-1110	/

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				<i>Application Number</i>	10/736,889
				<i>Filing Date</i>	12/15/2003
				<i>First Named Inventor</i>	Georges et al.
				<i>Art Unit</i>	1645
				<i>Examiner Name</i>	TBA
Sheet	6	of	7	Attorney Docket Number	112418.147/AUR-013

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		WEHNER et al., Expression levels of hsc70 and hsp60 are developmentally regulated during B-cell maturation and not associated to childhood c-ALL at presentation or relapse, Eur. J. Haematol., 71, 2003, pp. 100-108		/	
		STEINERT et al., A High Molecular Weight Intermediate Filament-associated Protein in BHK-21 Cells Is Nestin, a Type VI Intermediate Filament Protein, The Journal of Biological Chemistry, Vol. 274, No. 14, 1999, pp. 9881-9890		/	
		STRELKOV et al., Molecular architecture of intermediate filaments, BioEssays, 25, 2003, pp. 243-251		/	
		TRAIL et al., Monoclonal antibody drug immunoconjugates for targeted treatment of cancer, Cancer Immunol. Immunother., 52, 2003, pp. 328-337		/	
		TREIB and KOTZ, Proteins expressed in osteosarcoma and serum levels as prognostic factors, The International Journal of Biochemistry & Cell Biology, 33, 2001, pp. 11-17		/	
		TUROWSKI et al., Vimentin Dephosphorylation by Protein Phosphatase 2A Is Modulated by the Targeting Subunit B55, Molecular Biology of the Cell, Vol. 10, 1999, pp. 1997-2015		/	
		WANG and LIU, Targeting Strategies in Cancer Gene Therapy, Acta Bochimica et Biophysica Sinica, 35(4), 2003, pp. 311-316		/	
		WU et al., High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment, PNAS, Vol. 97, No. 15, 2000, pp. 8495-8500		/	
		YOKOTA et al., Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms, Cancer Research, Vol. 52, Issue 12, 1992, pp. 3402-3408		/	
		YASUAKI et al., 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity, Journal of Immunology, Vol. 151, No. 10, 1993, pp. 5516-5524			

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		<i>Complete if Known</i>	
		<i>Application Number:</i>	10/736,889
		<i>Filing Date:</i>	12/15/2003
		<i>First Named Inventor:</i>	Georges et al.
		<i>Art Unit:</i>	1645
		<i>Examiner Name:</i>	TBA
		<i>Attorney Docket Number:</i>	112418.147/AUR-013
Sheet	7	of	7
(Use as many sheets as necessary.)			

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.